CORE--VIROLOGY CORE LABORATORY

核心--病毒学核心实验室

• 批准号: 3769658
• 负责人: MOSTAFA NOKTA
• 金额: --
• 依托单位: UNIVERSITY OF TEXAS MED BR GALVESTON
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3769658
• 关键词: Adenoviridae; Epstein Barr virus; HIV envelope protein gp120; HIV infections; acyclovir; antiAIDS agent; biomedical facility; blood tests; cooperative study; cytomegalovirus; drug tolerance; ganciclovir; herpes simplex virus 1; herpes simplex virus 2; human immunodeficiency virus; human subject; microorganism disease chemotherapy; opportunistic infections; urinalysis; virus antigen; virus diseases

The core virology laboratory will be responsible for performing protocol mandated virology testing. This will serve the ACTU in this institution as well as other ACTG units without virology core laboratories. HIV, CMV, EBV, VZV, and HSV serologic studies will be performed at baseline and thereafter as mandated by the clinical protocol. Primarily, initial baseline virology determinations will be done before the initiation of therapy, and at frequent intervals thereafter, these will include virus isolations and HIV serum P-24 Ag determinations. HIV isolations will be from peripheral blood, unless protocol mandates otherwise. HIV plasma viremia may be determined, when indicated, as a potential marker of antiretroviral therapeutic efficacy. The virology core will also isolate and quantify other opportunistic viruses that commonly infect HIV patients, particularly cytomegalovirus (CMV), herpes simplex virus (HSV), and adenovirus. Quantitative CMV urine cultures are available for use as a marker of anticytomegaloviral therapeutic efficacy. All isolates recovered from patients on specific antiviral therapy will be stored for use, as needed, for antiviral resistance testing. Rapid CMV culture recovery may be facilitated using the shell vial centrifugation method. Sensitivity testing of patient derived viral isolates to antiviral compounds (e.g. ganciclovir-resistant CMV and acyclovir-resistant HSV) will be done as needed. Measurement of other surrogate markers of HIV markers as gp120, nef protein, neopterin, B2 microglobulin, and C1q and other markers as indicated by study protocols. Moreover, the laboratory will continue to be involved in the development and evaluation of novel virology diagnostic tools as they become available and in the modification of existent methodologies to increase their sensitivities and specificities. The laboratory will also participate in the quality assurance program established by the ACTG in order to standardize the results obtained.

核心病毒学实验室将负责执行方案 强制病毒学检测。这将为该机构中的ACTU提供服务 以及其他没有病毒学核心实验室的ACTG单位。艾滋病毒，巨细胞病毒， EBV、VZV和HSV血清学研究将在基线和 之后，按照临床方案的要求。主要是首字母 基线病毒学测定将在启动之前进行 治疗，此后每隔一段时间，这些治疗将包括病毒 HIV病毒分离及血清P-24抗原测定。艾滋病病毒分离株将是 从外周血中提取，除非协议另有规定。HIV血浆 病毒血症可被确定为潜在的标记物。 抗逆转录病毒治疗效果。病毒学核心也会分离出 并量化其他通常感染艾滋病毒患者的机会性病毒， 尤其是巨细胞病毒、单纯疱疹病毒和 腺病毒。CMV尿液定量培养可作为 抗巨细胞病毒治疗疗效的标志物。所有分离株均已恢复 来自接受特定抗病毒治疗的患者的信息将被储存起来以供使用，因为 需要，用于抗病毒耐药性测试。CMV培养的快速恢复可能 使用贝壳小瓶离心法可以方便地提取。敏感度 患者来源的病毒分离株对抗病毒化合物的检测(例如 更昔洛韦耐药巨细胞病毒和阿昔洛韦耐药单纯疱疹病毒)将按 需要的。HIV标志物的其他替代标志物如gp120的测量， NEF蛋白、新喋呤、B_2微球蛋白、C1q等标志物 由研究方案显示。此外，实验室将继续 参与开发和评估新的病毒学诊断方法 可用的工具以及现有工具的修改 提高其敏感性和特异性的方法。这个 实验室还将参加质量保证计划 由ACTG建立，以使所获得的结果标准化。